What West Pharmaceutical Services's latest 10-Q says: 9 signals
West Pharmaceutical Services filed its latest 10-Q with the SEC on Jul 23, 2026. It discusses CEO change, CHRO change and cybersecurity incident.
Public (WST)Plastics Manufacturing10,000+ employeeswestpharma.comLinkedIn
- Filed
- Jul 23, 2026
- Filings
- 2
- Signals
- 19
10-Q · latest 10
What West Pharmaceutical Services's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 9 signals
A recent cyberattack resulted in encrypted systems and stolen data, forcing a temporary global shutdown of operations.
artificial intelligence
New executive Michel Lagarde's employment agreement dated May 31, 2026, signals CEO change.
The company filed an executive employment agreement for Michel Lagarde, indicating a change in top leadership.
Facing securities class action lawsuit alleging violations of the Securities Exchange Act.
The company and certain officers are defendants in a class action lawsuit over public statements and stock transactions, creating significant legal risk and likely increasing spend on legal services and e-discovery tools.
CHRO Annette Favorite adopted a Rule 10b5-1 trading plan, signaling potential departure.
CHRO Annette Favorite established a plan on June 2, 2026, to sell up to 15,659 shares starting in September 2026.
Anticipates significant and increasing costs to mitigate data security risks after major incident.
Following a material cyberattack, the company explicitly states that costs to enhance systems and prevent future attacks will be significant and are likely to increase.
Identifies dependency on single-source Japanese partner Daikyo for critical materials.
The company explicitly states its dependence on its Japanese partner and affiliate, Daikyo, as a single-source supplier for critical products.
Daikyo
Facing margin pressure from rising costs of petroleum-based raw materials.
The company is being forced to implement price increases to offset rising production costs, specifically citing petroleum-based raw materials.
- SEC EDGAR
10-Q
Filed · 10 signals
Facing securities class action lawsuit from New England Teamsters Pension Fund.
A class action lawsuit filed in May 2025 alleges violations of the Securities Exchange Act, creating significant legal costs, management distraction, and potential financial liability.
West Pharma to divest its SmartDose 3.5mL on-body delivery system product line.
The company has classified its SmartDose 3.5mL product line and related facilities as 'held for sale,' signaling an imminent divestiture.
Daikyo
Incurred a $12.0M one-time tax cost from an internal legal entity restructuring in Q1 2026.
The company executed a significant internal legal entity restructuring, resulting in a material one-time tax expense.
$12M
One-time tax cost from internal legal entity restructuring
Showing 10 of 19 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
West Pharmaceutical Services earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Raised full-year revenue and earnings guidance on strong performance.The company increased its FY25 revenue forecast to $3.06-$3.07 billion and adjusted EPS to $7.06-$7.11, indicating strong business momentum and financial health. This suggests available budget and confidence in future growth. | |
| Annex 1 upgrade initiative accelerating, now expected to drive 200bps of growth.The company is seeing stronger-than-expected demand for upgrades related to new EU regulations (Annex 1), with 375 projects ongoing. This initiative is a key growth driver, creating opportunities for vendors who can support quality and compliance upgrades. | |
| Launching new drug handling business, expecting $20M revenue in 2026.The company is commercializing a new drug handling business in its Dublin facility, with production ramping in early 2026. This expansion into a new service line creates opportunities for vendors supporting new product introductions and manufacturing processes. | |
| Actively hiring and training to expand manufacturing capacity in Germany.The company is investing in its workforce to resolve production constraints at a key HVP manufacturing site. This indicates budget for talent acquisition, training, and operational support to fuel growth. | |
| Capital expenditures decreasing to $275M after a period of elevated spending.While CapEx is down 23% year-to-date compared to last year, the company is still on track to spend a substantial $275 million in 2025. This normalization frees up cash flow but still represents significant investment in facilities and equipment. | |
| New CFO is establishing a new capital allocation policy.The new CFO is actively reviewing and defining a new capital allocation policy to better deploy the company's strong cash flow. This strategic shift could influence future M&A, buybacks, and major internal investment decisions, creating openings for financial and strategic advisory services. |
Signal API · MCP
Track West Pharmaceutical Services with the Signal API
One POST /v1/companies/enrich call with westpharma.com returns West Pharmaceutical Services 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"westpharma.com","signal_types":["sec-10q"],"limit":20}'Questions about West Pharmaceutical Services 10-Q
When did West Pharmaceutical Services file its latest 10-Q?
What did West Pharmaceutical Services disclose in its latest 10-Q?
What did West Pharmaceutical Services say on its recent earnings calls?
Where can I read West Pharmaceutical Services's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .